BostonGene, ImmunoGenesis Partner to Accelerate Development of Immune Checkpoint Inhibitor

BostonGene, developer of a tumor and immune biology AI model, and ImmunoGenesis, a clinical-stage biotechnology company, announced a strategic partnership.

The collaboration between the two companies spurs acceleration of clinical development for ImmunoGenesis’ lead program, IMGS-001. To explain further, this is a cytotoxic immune checkpoint inhibitor targeting programmed death-ligands 1 and 2 (PD-L1, PD-L2 respectively).

Prior to this announcement, IMGS-001’s safety and efficacy were the focus of a Phase Ia/b dose-escalation and dose-expansion trial. The trial involves patients with solid tumors for whom standard-of-care therapies have produced a failure to respond. By investigating the impact of IMGS-001 against a patient’s unique immune and genetic profile, the trial will then identify most likely respondents.

How Partners Will Improve Immune Biology

BostonGene will apply its AI-driven, multiomic platform to perform deep molecular characterization of these patients. In other words, the partnership integrates high-resolution spatial biology with systemic immune monitoring to generate critical data.

The collaboration aims to move beyond traditional biomarker analysis to “reshape the tumor microenvironment.”

BostonGene, ImmunoGenesis Leaders Speak

“This partnership represents a significant leap beyond conventional monitoring,” said Charles Schweizer, PhD, ImmunoGenesis Senior Vice President of Clinical Development. “By embedding BostonGene’s AI-powered insights into our clinical framework, we are decoding precise cellular and molecular pathways driving clinical outcomes. This clarity will allow us to move with greater speed and precision, ultimately strengthening the potential of IMGS-001.”

“Modern oncology demands a shift from broad application to data-driven precision,” said BostonGene Chief Medical Officer Nathan Fowler, MD. “We are defining the mechanism by which IMGS-001 overcomes immunotherapy resistance. This critical collaboration delivers important evidence needed to guide the next generation of precision immunotherapy.”